Annexon Inc (ANNX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.23 (+1.44%), Market cap $0.85B, 52-week low–high $1.97 ~ $6.96.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical tri
Financial statements, price targets, institutional (13F) holdings and related news for Annexon Inc are updated in real time on BlackAll Trade.
Annexon Inc trades at $4.23 (+1.44%). Real-time quotes and charts are available on BlackAll Trade.
Annexon Inc has a market cap of about $0.85B.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-lengt